Mackenzie Hemje, MD
Family Medicine · Hastings, NENPI 1700291085
Payments from drug & device makers
Across 279 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$849
- AbbVie$811
- Novo Nordisk$652
- Lilly USA, LLC$438
- Pfizer$368
- Boehringer Ingelheim$206
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,607100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $849 |
| AbbVie(2 entities) | 48 | $811 |
| Novo Nordisk | 45 | $652 |
| Lilly USA, LLC | 34 | $438 |
| Pfizer | 39 | $368 |
| Boehringer Ingelheim | 15 | $206 |
| Amgen | 13 | $175 |
| Johnson & Johnson | 8 | $163 |
| Bayer | 9 | $124 |
| Exact Sciences | 6 | $93 |
| Astellas Pharma US Inc | 5 | $89 |
| Merck | 4 | $74 |
| Organon | 4 | $70 |
| Sanofi-aventis U.S. LLC | 5 | $68 |
| Sanofi Pasteur Inc. | 4 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Novartis | 2 | $34 |
| Optinose US, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| GSK | 2 | $23 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$733
- BREZTRI$473
- AIRSUPRA$362
- SYMBICORT$260
- BEVESPI AEROSPHERE$111
- BREZTRI AEROSPHERE$103
How this compares
$4,613 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $82,173 |
| EliquisApixaban | 120 | $72,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $50,553 |
| XareltoRivaroxaban | 54 | $41,716 |
| JardianceEmpagliflozin | 42 | $35,617 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $16,894 |
| FarxigaDapagliflozin Propanediol | 23 | $16,305 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 47 | $10,393 |
| MounjaroTirzepatide | 11 | $10,076 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,439 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,828 |
| MyrbetriqMirabegron | 14 | $6,733 |
| Potassium Chloride | 243 | $6,163 |
| InvokanaCanagliflozin | 11 | $5,930 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $4,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $652 | $82,17391 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $23 | $77,214145 claims |
| PfizerEliquis | $368 | $72,502120 claims |
| Johnson & JohnsonXarelto, Invokana | $163 | $47,64665 claims |
| Boehringer IngelheimJardiance | $206 | $35,61742 claims |
| AstraZenecaFarxiga | $849 | $16,30523 claims |
| Lilly USA, LLCMounjaro | $438 | $10,07611 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $6,73314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Hastings
- Timothy ZimmermanHastings$41K
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.